Medicare’s New Negotiation Era: How Part B Inclusion Reshapes Pricing, Access, and Manufacturer Risk
For the first time, CMS has selected drugs for negotiation based on combined Part B and Part D spend. This marks a new era in the implementation of the Medicare Drug Price Negotiation Program, expanding the universe of products at risk, and it introduces new uncertainties around commercial‑channel pricing, duplicate discounts, and assessments of clinical and economic value. This white paper breaks down what this means for manufacturers and outlines the strategic steps companies should take now to prepare for negotiation impacts. (March 2026)
Download the White Paper
"*" indicates required fields